This analysis revealed that treatment strategies for real-world patients with EGFR-mutated NSCLC are heterogeneous, reflecting, at that time, the use of different TKIs in front-line therapy but also the complexity of second-line treatments, for which patients carrying the T790M mutation were treated with osimertinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.